United Therapeutics (NASDAQ:UTHR) Upgraded at Bank of America

Bank of America upgraded shares of United Therapeutics (NASDAQ:UTHR) from an underperform rating to a neutral rating in a report released on Monday morning, MarketBeat.com reports. They currently have $314.00 target price on the biotechnology company’s stock.

A number of other analysts have also weighed in on the stock. HC Wainwright restated a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $395.67.

United Therapeutics Stock Down 0.2 %

NASDAQ:UTHR opened at $284.25 on Monday. United Therapeutics has a 52 week low of $233.28 and a 52 week high of $417.82. The company has a fifty day simple moving average of $314.88 and a two-hundred day simple moving average of $348.12. The company has a market cap of $12.77 billion, a price-to-earnings ratio of 12.48, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the firm posted $4.36 EPS. On average, analysts expect that United Therapeutics will post 24.48 EPS for the current year.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $911,330.28. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at $11,261,606.58. The trade was a 23.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 81,500 shares of company stock valued at $27,322,440 over the last ninety days. Insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Signaturefd LLC grew its holdings in shares of United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after buying an additional 30 shares during the last quarter. Parallel Advisors LLC lifted its position in United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after acquiring an additional 30 shares during the period. Anchor Investment Management LLC grew its stake in shares of United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 30 shares during the last quarter. Great Lakes Advisors LLC increased its holdings in shares of United Therapeutics by 1.6% in the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after purchasing an additional 31 shares during the period. Finally, Oregon Public Employees Retirement Fund increased its holdings in shares of United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after purchasing an additional 33 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.